Bixalomer vs Colestilan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Phosphate binder · full Chronic Kidney Disease pipeline
Bixalomer · Kiklin
Marketed by Astellas Pharma under a licence from Amgen
NCT00892749 · Phase 3 · completed
The study enrolled 248 participants but was open-label, single-arm, and had no placebo or active comparator, so it could not provide a controlled comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Change from baseline in serum phosphorus level at the end of treatment (Baseline and Week 12 or treatment discontinuation): Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001. (met)
Result source: NCT01742585
Colestilan · Cholebine / BindRen
Marketed by Fuji Pharma Co., Ltd. and partners
NCT00542815 · Phase 3 · completed
This open-label, non-randomized, flexible-dose Phase III extension study gave colestilan (MCI-196) for up to 52 weeks to 632 dialysis patients with hyperphosphataemia who came from earlier colestilan studies, with a sevelamer group carried over from study E07. It was designed as a long-term safety study, and its phosphorus outcome is descriptive with no formal between-group test, so there is no met or missed result. Source: CT.gov posted results.
Reported efficacy
The Change in Serum Phosphorus for MCI-196 and Sevelamer (52 weeks (Baseline-52 weeks)): Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results). (not_applicable)
Result source: NCT00542815
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bixalomer | Colestilan |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT01742585 | —Not posted · NCT00506441 |
| UACR, % change | —Not posted · NCT01742585 | —Not posted · NCT00506441 |
| eGFR slope | —Not posted · NCT01742585 | —Not posted · NCT00506441 |
| Haemoglobin, change | —Not posted · NCT01742585 | —Not posted · NCT00506441 |
Kidney composite outcome
- Bixalomer
- —Not posted · NCT01742585
- Colestilan
- —Not posted · NCT00506441
UACR, % change
- Bixalomer
- —Not posted · NCT01742585
- Colestilan
- —Not posted · NCT00506441
eGFR slope
- Bixalomer
- —Not posted · NCT01742585
- Colestilan
- —Not posted · NCT00506441
Haemoglobin, change
- Bixalomer
- —Not posted · NCT01742585
- Colestilan
- —Not posted · NCT00506441
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Bixalomer: 1 of 5 rows · Colestilan: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bixalomer | Colestilan |
|---|---|---|
| Serum Phosphorus Change mg/dL absolute change · mg/dL | -0.78 vs 0.2 placebo mg/dL @ 12wka,b,c NCT01742585 · Phase 3 · sponsor-reported, not registry data | -1.23 vs -2.26 Sevelamer mg/dL @ 52wkd,a,b,c NCT00542815 · Phase 3 show 1 more dose-1.47 vs -2.26 Sevelamer mg/dL @ 52wk NCT00542815 · Phase 3 |
| Dropout rate | — | 24.5%MCI-196 From E07 / E08 Studiese NCT00542815 · Phase 3 show 17 more results42.1%MCI-196 From E07 Study NCT00542815 · Phase 3 —MCI-196 From E07/E08 Studies NCT00542815 · Phase 3 36.4%MCI-196 (Open-label Period) NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Placebo-Controlled Period NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Placebo-controlled Withdr NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Double-blind Period) NCT00506441 · Phase 3 · monotherapy —MCI-196 (Open-label Period) NCT00506441 · Phase 3 · monotherapy 47.4% NCT00772382 · Phase 3 · registry result, not featured evidence 18.9%MCI-196 (Active) + Simvastatin (Pl NCT00858637 · Phase 3 · registry result, not featured evidence · combination —MCI-196 (Active) + Simvastin (Plac NCT00858637 · Phase 3 · registry result, not featured evidence · combination 39.2%15 g NCT00542386 · Phase 3 · registry result, not featured evidence 36.9%12 g NCT00542386 · Phase 3 · registry result, not featured evidence 33.3%9 g NCT00542386 · Phase 3 · registry result, not featured evidence 27.5%6 g NCT00542386 · Phase 3 · registry result, not featured evidence 41.3%3 g NCT00542386 · Phase 3 · registry result, not featured evidence —Candesartan Plus Colestilan (Day 7 NCT01976572 · Phase 1 · registry result, not featured evidence · combination —Colestilan Alone (Day 3 to 6) NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | — | 4.4%MCI-196 From E07 / E08 Studiese NCT00542815 · Phase 3 show 17 more results7.9%MCI-196 From E07 Study NCT00542815 · Phase 3 —MCI-196 From E07/E08 Studies NCT00542815 · Phase 3 17%MCI-196 (Open-label Period) NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Placebo-Controlled Period NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Placebo-controlled Withdr NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Double-blind Period) NCT00506441 · Phase 3 · monotherapy —MCI-196 (Open-label Period) NCT00506441 · Phase 3 · monotherapy 16.4% NCT00772382 · Phase 3 · registry result, not featured evidence 11%MCI-196 (Active) + Simvastatin (Pl NCT00858637 · Phase 3 · registry result, not featured evidence · combination —MCI-196 (Active) + Simvastin (Plac NCT00858637 · Phase 3 · registry result, not featured evidence · combination 12.7%15 g NCT00542386 · Phase 3 · registry result, not featured evidence 7.8%12 g NCT00542386 · Phase 3 · registry result, not featured evidence 7.1%9 g NCT00542386 · Phase 3 · registry result, not featured evidence 6.9%6 g NCT00542386 · Phase 3 · registry result, not featured evidence 1%3 g NCT00542386 · Phase 3 · registry result, not featured evidence —Candesartan Plus Colestilan (Day 7 NCT01976572 · Phase 1 · registry result, not featured evidence · combination —Colestilan Alone (Day 3 to 6) NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy |
| Serious AEs | — | —MCI-196 From E07 / E08 Studiese NCT00542815 · Phase 3 show 17 more results40.8%MCI-196 From E07 Study NCT00542815 · Phase 3 17.1%MCI-196 From E07/E08 Studies NCT00542815 · Phase 3 16%MCI-196 (Open-label Period) NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 4%MCI-196 (Placebo-Controlled Period NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 —MCI-196 (Placebo-controlled Withdr NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 11.6%MCI-196 (Double-blind Period) NCT00506441 · Phase 3 · monotherapy 15.1%MCI-196 (Open-label Period) NCT00506441 · Phase 3 · monotherapy 54.3% NCT00772382 · Phase 3 · registry result, not featured evidence 12.5%MCI-196 (Active) + Simvastatin (Pl NCT00858637 · Phase 3 · registry result, not featured evidence · combination —MCI-196 (Active) + Simvastin (Plac NCT00858637 · Phase 3 · registry result, not featured evidence · combination 5%15 g NCT00542386 · Phase 3 · registry result, not featured evidence 6.9%12 g NCT00542386 · Phase 3 · registry result, not featured evidence 2%9 g NCT00542386 · Phase 3 · registry result, not featured evidence 1%6 g NCT00542386 · Phase 3 · registry result, not featured evidence 2.9%3 g NCT00542386 · Phase 3 · registry result, not featured evidence 0%Candesartan Plus Colestilan (Day 7 NCT01976572 · Phase 1 · registry result, not featured evidence · combination 0%Colestilan Alone (Day 3 to 6) NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | — | show 14 more resultsvomiting 16.7% (placebo 0%) diarrhoea 13% (placebo 1.9%) nausea 9.3% (placebo 1.9%) NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 haemodialysis-induced symptom 6% (placebo 0%) bronchitis 4% (placebo 1.9%) constipation 4% (placebo 0%) NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3 nausea 4.7% (placebo 0%) arthralgia 3.5% (placebo 1.2%) diarrhoea 3.5% (placebo 3.6%) NCT00506441 · Phase 3 · monotherapy diarrhoea 9% (placebo 3.6%) nausea 8.6% (placebo 0%) vomiting 7.3% (placebo 0%) NCT00506441 · Phase 3 · monotherapy nausea 22.4% vomiting 20.7% diarrhoea 19.8% NCT00772382 · Phase 3 · registry result, not featured evidence headache 9.4% anaemia 8.6% dyspepsia 7.8% NCT00858637 · Phase 3 · registry result, not featured evidence · combination 15 g nausea 19.8% (placebo 0%) dyspepsia 8.9% (placebo 0.8%) abdominal distension 5.9% (placebo 3%) NCT00542386 · Phase 3 · registry result, not featured evidence 12 g nausea 18.6% (placebo 0%) vomiting 10.8% (placebo 1.5%) abdominal distension 6.9% (placebo 3%) NCT00542386 · Phase 3 · registry result, not featured evidence 9 g nausea 12.2% (placebo 0%) vomiting 8.2% (placebo 1.5%) dyspepsia 7.1% (placebo 0.8%) NCT00542386 · Phase 3 · registry result, not featured evidence 6 g nausea 8.8% (placebo 0%) dyspepsia 7.8% (placebo 0.8%) hypertension 5.9% (placebo 3%) NCT00542386 · Phase 3 · registry result, not featured evidence 3 g diarrhoea 4.8% (placebo 5.3%) asthenia 3.8% (placebo 0.8%) dyspepsia 3.8% (placebo 0.8%) NCT00542386 · Phase 3 · registry result, not featured evidence dizziness 11.1% fatigue 11.1% headache 11.1% NCT01976572 · Phase 1 · registry result, not featured evidence · combination fatigue 11.1% headache 11.1% nausea 11.1% NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 12 weeks versus 52 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 15 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Colestilan
show 1 more result
show 7 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bixalomer's landscape · Colestilan's landscape